Estradiol; Progesterone Patent Expiration
Estradiol; Progesterone is Used for relieving menopause symptoms, including vasomotor symptoms. It was first introduced by Mayne Pharma Llc
Estradiol; Progesterone Patents
Given below is the list of patents protecting Estradiol; Progesterone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bijuva | US10052386 | Progesterone formulations | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US10206932 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US10639375 | Progesterone formulations | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US10675288 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US10806740 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11033626 | Progesterone formulations having a desirable pk profile | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11103513 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11103516 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11110099 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11166963 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11529360 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11793819 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US11865179 | Progesterone formulations having a desirable PK profile | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8633178 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8846648 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8846649 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8933059 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8987237 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8993548 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US8993549 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US9006222 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US9114145 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US9114146 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
| Bijuva | US9301920 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Estradiol; Progesterone's Family Patents
Explore Our Curated Drug Screens
Estradiol; Progesterone Generic API Manufacturers
Only one generic application has been filed for Estradiol; Progesterone.
Given below is the list of companies who have filed for Estradiol; Progesterone generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL PHARMS
Amneal Pharmaceuticals Of New York Llc has filed for 1 generic for Estradiol; Progesterone. This 1mg;100mg version comes by the name ESTRADIOL AND PROGESTERONE. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG; 100MG | capsule | Discontinued | ORAL | N/A | May 16, 2022 |